Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Spironolactone in Alcohol Use Disorder (SAUD): A Double-Blind, Placebo-Controlled, Ascending Dose, Phase 1b Study

NCT05807139 is registered in ClinicalTrials.gov with National Institute on Drug Abuse (NIDA) as lead sponsor.

NCT NCT05807139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05807139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Spironolactone in Alcohol Use Disorder (SAUD): A Double-Blind, Placebo-Controlled, Ascending Dose, Phase 1b Study
Lead sponsor
National Institute on Drug Abuse (NIDA)
Phase
Phase 1
Overall status
Recruiting
Start date
July 13, 2023
Completion date
April 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder